OCT-980 is designed to stabilize misfolded rhodopsin and restore proper cellular trafficking. By directly targeting the ...

J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering.

Shareholders also cast 13,812,075 (99.560%) votes for and withheld 61,000 (0.440%) votes from the appointment of ...

FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s ...

Kyverna Therapeutics' miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff ...

WeGuide Pty Ltd will receive A$1.9 million to build a world first platform in developing commercial multi-modal biomarkers.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for ...

PharmFormulator is a source-linked research platform with over 1,200 U.S. ophthalmic drug-product records, including ...

The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.

In Thursday’s Senate committee meeting, FDA commissioner nominee Heidi Overton was repeatedly questioned about her ability to retain the FDA’s independence under President Donald Trump, as well as her ...

While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body ...

Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.